Key facts
- This page summarizes Brian Goff's Form 4 filing for Intellia Therapeutics, Inc. (NTLA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2024, 17:14.
Brian Goff - 13 Jun 2024 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)
- Reporting relationship
- Director
- Issuer ticker
- NTLA
- Reported as of
- 13 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2024, 17:14:33 UTC
- Prior SEC filing
- 07 Jun 2024
- Next SEC filing
- 12 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- James Basta, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian Goff filed Form 4 for Intellia Therapeutics, Inc. (NTLA) on 17 Jun 2024.
Change
- Previous filing in this sequence was filed on 07 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NTLA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +15,409
- Change %
- Price
- $0.000000
- Shares after
- 15,409
- Date
- 13 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NTLA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +22,297
- Change %
- Price
- $0.000000
- Shares after
- 22,297
- Date
- 13 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,297
- Exercise price
- $25.96
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
Footnote F2
This option was granted on June 13, 2024 with respect to 22,297 shares of Common Stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan, with 33 1/3 % vesting on June 13, 2025 and the remaining 66 2/3% vesting in 8 substantially equal quarterly installments thereafter.